The SGLT2 Inhibitor Canagliflozin Prevents Increased Lipid Oxidation in the Heart following High-Fat Feeding

被引：1
|
作者：
Flores, Itzel
Shannon, Chris
Fourcaudot, Marcel
Bakewell, Terry
Norton, Luke
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-165-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
165-LB
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Canagliflozin, a SGLT2 Inhibitor Improves Skeletal Muscle Function in High-Fat Diet-Fed Obesity Mice
    Komatsu, Tomohiro
    Abe, Satomi
    Nakashima, Shihoko
    Soneda, Eri
    Higaki, Yasuki
    Uehara, Yoshinari
    CIRCULATION, 2019, 140
  • [2] Canagliflozin, An SGLT2 Inhibitor, Prevents Lung Remodeling in Chronic Left Ventricular Failure
    Kanuparthy, M.
    Harris, D. D.
    Hamze, J.
    Broadwin, M.
    Stone, C.
    Banerjee, D.
    Sellke, F. W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [3] CANAGLIFLOZIN, AN SGLT2 INHIBITOR ATTENUATES ISCHAEMIA/REPERFUSION INJURY IN THE NONDIABETIC HEART
    Lim, Ven Gee
    Arjun, Sapna
    Bell, Robert
    Yellon, Derek
    HEART, 2019, 105 : A146 - A147
  • [4] SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart
    Lim, Ven G.
    Bell, Robert M.
    Arjun, Sapna
    Kolatsi-Joannou, Maria
    Long, David A.
    Yellon, Derek M.
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2019, 4 (01): : 15 - 26
  • [5] Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects
    Kasichayanula, S.
    Liu, X.
    Zhang, W.
    Pfister, M.
    Reele, S. B.
    Aubry, A. -F.
    LaCreta, F. P.
    Boulton, D. W.
    DIABETES OBESITY & METABOLISM, 2011, 13 (08): : 770 - 773
  • [6] SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats
    Yokono, Masanori
    Takasu, Toshiyuki
    Hayashizaki, Yuka
    Mitsuoka, Keisuke
    Kihara, Rumi
    Muramatsu, Yuko
    Miyoshi, Sousuke
    Tahara, Atsuo
    Kurosaki, Eiji
    Li, Qun
    Tomiyama, Hiroshi
    Sasamata, Masao
    Shibasaki, Masayuki
    Uchiyama, Yasuo
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2014, 727 : 66 - 74
  • [7] The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma
    Jojima, Teruo
    Wakamatsu, Sho
    Kase, Masato
    Iijima, Toshie
    Maejima, Yuko
    Shimomura, Kenju
    Kogai, Takahiko
    Tomaru, Takuya
    Usui, Isao
    Aso, Yoshimasa
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (20)
  • [8] The SGLT2 inhibitor canagliflozin suppresses lipid synthesis and interleukin-1 beta in ApoE deficient mice
    Day, Emily A.
    Ford, Rebecca J.
    Lu, Jessie H.
    Lu, Rachel
    Lundenberg, Lucie
    Desjardins, Eric M.
    Green, Alex E.
    Lally, James S., V
    Schertzer, Jonathan D.
    Steinberg, Gregory R.
    BIOCHEMICAL JOURNAL, 2020, 477 (12) : 2347 - 2361
  • [9] The SGLT2 Inhibitor Dapagliflozin Prevents the Loss of Pancreatic Function in the High Fat Fed Female (HFFF) ZDF Rat
    Macdonald, Ruth F.
    Westgate, Leanne
    Poucher, Simon M.
    Mayers, Rachel M.
    Whaley, Jean M.
    DIABETES, 2009, 58 : A380 - A381
  • [10] The SGLT2 inhibitor dapagliflozin prevents the disruption of pancreatic islet morphology in the high fat-fed-female ZDF rat
    Peel, J. E.
    Macdonald, R. F.
    Westgate, L.
    Jones, H. B.
    Poucher, S. M.
    Mayers, R. M.
    Whaley, J.
    DIABETOLOGIA, 2009, 52 : S36 - S36
12345